JC Medical News
First Patient in the U.S. Treated with the J-Valve TF System
The first patient in the U.S. was treated with the J-Valve TF System by Dr. Dean Kereiakes of The Christ Hospital Heart and Vascular Center in Ohio. “Sharon was actually turned down by multiple surgeons, thought she would be too high-risk with her chance of dying in the procedure. This valve is specifically designed to treat leaky aortic valves,” said Dr. Kereiakes on a #HeartMonth segment. Watch video
Cardiology Today’s Intervention (Healio) – First US patient implanted with novel TAVR valve
January 7th, 2019 – Read the Article
Medical Device and Diagnostic Industry (MD+DI) – First World-Wide Patient Treated – JC Medical Becoming Serious Challenger in TAVR Fray
May 31st, 2018 – Read the Article
About The J-Valve™ System
The J·Valve™ Transcatheter Aortic Valve Replacement (TAVR) system* is a revolutionary next generation heart valve implantation system. The system is designed to replace a patient’s failed native aortic heart valve. The J·Valve™ TAVR System consists of a uniquely designed transcatheter aortic valve and delivery device designed by JC Medical in the USA. Other systems are indicated for aortic stenosis alone and aortic bioprostheses are often difficult to position accurately. The J·Valve™ system was designed to address these problems in order to create a more useful and reliable replacement transcatheter aortic valve for surgeons and patients.
This system can be used to treat:
- Severe aortic stenosis
- Pure aortic regurgitation
- A combination of aortic stenosis and regurgitation, also known as
Other features of the system:
- System is easy to learn and simple to operate
- Automatic anatomic alignment with the native aortic root
*This system has not yet been approved by the FDA and is currently not for sale.
The J·Valve™ Transcatheter Aortic Valve
positions itself according to the anatomy
of the native aortic annulus. It naturally
slides into place, allowing doctors to
rely on tactile feedback to achieve
*This system has not yet been approved
by the FDA and is currently not for sale.
Key Design Features:
- U-shaped “anchor rings” facilitate accurate self-positioning of the replacement aortic valve
- Low profile design minimizes risk of coronary blockage
- With four different valve sizes, the system ensures a perfect fit for each patient
Doctors can perform transcatheter replacement
aortic valve implantations accurately because
the intuitive design of the delivery device is
easy to use.
*This system has not yet been approved by the FDA
and is currently not for sale.
Key Design Features:
- Valve loads seamlessly into the nosecone
- Locking mechanism ensures valve deployment at the correct time
- Two control knobs release the valve into place
First in-human experience of a new generation transfemoral transcatheter aortic valve for the treatment of severe aortic regurgitation: the J-Valve transfemoral system. EuroIntervention – 2018
The first transapical transcatheter aortic valve-in-valve implantation using the J-valve system into a failed biophysio aortic prosthesis in a patient with high risk of coronary obstruction. Catheter Cardiovasc Interv. – 2018
Transapical transcatheter aortic valve replacement for aortic regurgitation with a second-generation heart valve. The Journal of Thoracic and Cardiovascular Surgery – 2018
Transapical transcatheter aortic valve replacement with a novel transcatheter aortic valve replacement system in high-risk patients with severe aortic valve diseases. The Journal of Thoracic and Cardiovascular Surgery – 2018
Transapical implantation of a self-expandable aortic valve prosthesis utilizing a novel designed positioning element. Catheterization and Cardiovascular Interventions – 2017
Transapical transcatheter aortic valve implantation using the J-Valve system: a 1-year follow-up study. The Journal of Thoracic and Cardiovascular Surgery – 2017
Transapical transcatheter aortic valve implantation using a new TAVI system for high-risk patients with severe aortic stenosis. Heart, Lung and Circulation – 2017Treatment of pure aortic regurgitation using a second-generation transcatheter aortic valve implantation system. The Journal of the American College of Cardiology (JACC) – 2016
Transapical implantation of a new second-generation transcatheter heart valve in patients with pure aortic regurgitation: a preliminary report. Interactive CardioVascular and Thoracic Surgery – 2015
A new transcatheter aortic valve replacement system for predominant aortic regurgitation implantation of the J-Valve and early outcome. JACC: Cardiovascular Interventions – 2015
Successful trans-apical aortic valve implantation for a high risk patient with aortic stenosis using a new second-generation TAVI device: J-Valve system. Journal of Cardiothoracic Surgery – 2015
JC Medical, Inc. is a privately held, venture-backed medical device company which develops Transcathether Aortic Valve Implantation (TAVI) systems. The company’s first product is a next generation TAVI system that addresses an unmet need in patients with aortic regurgitation and aortic stenosis.